Dr. Scott M. Rocklage is a man of many talents and many experiences. He received a Ph.D. in Chemistry from the Massachusetts Institute of Technology, and B.S. in Chemistry from the University of California, and he also won FDA approval of three U.S. Drug Applications such as Omniscan, Teslascan, and Cubicin. Rocklage’s business ”is a life science-based venture capital firm”. Dr. Rocklage served as President and Chief Executive Officer of Nycomed Salutar, Inc. from 1990 to 1994 as well as Chief Executive Officer, President and Chairman of Nycomed Interventional, Inc. from 1992 to 1994. He then became President of Cubist Pharmaceuticals Inc and Protana in July of 1994 to March 2001 soon became its Founding Chief Executive Officer from July of 1994 to June of 2003. From March 2000 to December 31, 2004, Rocklage served as Chairman of Cubist Pharmaceuticals Inc. In 2003, he joined 5AM Venture Management LLC and has been a managing partner up to 2004. Dr. Rocklage soon served Executive Chairman at Ilypsa, Inc. from August 2004 to March 11, 2015 and served as a Director of Pulmatrix, Inc. since March 2006 until March 13, 2017 while also serving as a Director of Relypsa, Inc. from August 2007 to June 19, 2014 and VBI Vaccines Director at EPIRUS Biopharmaceuticals, Inc. on July 15, 2014 until July 25, 2016. A man of many talents cannot describe all the things Dr. Rocklage has achieved throughout the years and what he does continues to amaze us. Maybe one day, other Chemistry majors will look up to him for inspiration and enlightenment.
Connect with Dr. Scott Rocklage on LinkedIn.